Compare Arista Networks Inc (ANET) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Arista Networks (ANET) trades at $188.67, down 1.9% over 24 hours, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with revenue growing from $4.4B in 2022 to $9.0B in 2025 and a net income margin of 38.37%. Recent earnings beats and raised 2026 guidance reflect robust AI-driven demand from hyperscalers like Meta and Microsoft.

Outlook remains positive due to AI data center expansion and Ethernet market growth, but high valuation multiples (P/E 59.71) pose risks if execution falters. Analyst consensus is strongly bullish with a $252.25 price target, though insider selling and competition require monitoring for sustained gains.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.